Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Operations: 2016-2025

Historic Cash from Operations for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to -$26.6 million.

  • Rhythm Pharmaceuticals' Cash from Operations fell 5.58% to -$26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.1 million, marking a year-over-year increase of 12.29%. This contributed to the annual value of -$113.9 million for FY2024, which is 16.36% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Cash from Operations is -$26.6 million, which was down 14.19% from -$23.3 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Cash from Operations high stood at -$18.8 million for Q4 2024, and its period low was -$53.6 million during Q1 2022.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Cash from Operations value was -$29.3 million (recorded in 2023), while the average stood at -$30.9 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Cash from Operations slumped by 59.95% in 2022, and later soared by 37.75% in 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Cash from Operations (Quarterly) stood at -$40.5 million in 2021, then climbed by 15.99% to -$34.0 million in 2022, then rose by 13.58% to -$29.4 million in 2023, then soared by 35.86% to -$18.8 million in 2024, then declined by 5.58% to -$26.6 million in 2025.
  • Its Cash from Operations was -$26.6 million in Q3 2025, compared to -$23.3 million in Q2 2025 and -$40.4 million in Q1 2025.